DARE
Dare Bioscience, Inc.
Key Financials
Net Income
$-13399274
↓ 230.6%
Revenue
$1.0M
↑ 10429.4%
Operating Income
$-13552334
↑ 42.2%
EPS (Diluted)
$-1.20
↓ 150.0%
Total Assets
$32.5M
↑ 46.9%
Total Liabilities
$29.6M
↑ 5.4%
Cash & Equivalents
$24.7M
↑ 57.4%
Shareholders' Equity
$2.8M
↑ 147.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| S-8 | 6/23/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DARE |
| Company Name | Dare Bioscience, Inc. |
| CIK | 1401914 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-926-7655 |